Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.

Molecular oncology - 1 Dec 2024

Ahmad Olfat, Ahmad Tahani, Pfister Stefan M

Abstract excerpt

In 2021, Suwala et al. described Primary Mismatch Repair Deficient IDH-mutant Astrocytoma (PMMRDIA) as a distinct group of gliomas. In unsupervised clustering, PMMRDIA forms distinct cluster, separate from other IDH-mutant gliomas, including IDH-mutant gliomas with secondary mismatch repair (MMR) deficiency. In the published cohort, three patients received treatment with an immune checkpoint blocker (ICB), yet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms
Share to DNA Mismatch Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH1 gene

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38339779
DOI: 10.1002/1878-0261.13598
PMCID: PMC11619801

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.PMID 38339779Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

IDH-mutant gliomas in children and adolescents - from biology to clinical trialsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.